 |
Vitro Diagnostics, doing business as VitroBiopharma, has discovered break-through technologies in medical applications
of
adult human cells. |
 |
Green fluorescent protein (GFP) labeled human MSC are shown (Catalog No. SC00A4) together with labeled chondrocytes (arrow) showing transfer of GFP from MSC to chondrocytes. See: White Paper for more information |
The Company’s stem cell technology focuses on adult stem cells that are derived from human tissues without sacrifice of embryos as is needed to generate embryonic stem cells. New advances have shown that stem cells with properties comparable to embryonic stem cells including differentiation into any cell type may be derived from adult cells. These so-called induced pluripotent stem cells (iPS) may obviate the need for embryonic stem cells in the future and also eliminate the ethical and religious controversy surrounding use of embryonic stem cells. We have products that are intended to support advancement of this technology and also have a proprietary position with respect to iPS which may enable use of any personal cell type such as those of hair follicles, blood, saliva, etc, for the generation of cells encompassing properties of embryonic stem cells including the capacity for replacement of any cell in the body. Full development of this technology may well lead to a revolution in regenerative medicine that allows development of individual “designer” stem cells from any cell for therapeutic applications involving new treatments of heart disease, cancer, diabetes or other conditions such as age-related hearing or vision loss through the individualized replacement of defective or degenerated cells. We plan involvement in this technological revolution both through the supply of critical components to advance the necessary basic research while at the same time developing patented technology essential to the commercialization of iPS technology.